^
Association details:
| Biomarker: | CXCR4 R338X |
|---|---|
| Cancer: | Waldenstrom Macroglobulinemia |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) + Ninlaro (ixazomib) (Proteasome inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up
Published date:
08/21/2020
Excerpt:
Fifteen patients (58%) had a CXCR4 mutation, of which 10 had nonsense mutations (5 had R338X, 4 had S338X, and 1 had G336X) and 5 had frameshift mutations (T318fs, L326fs, K327fs, S347fs, and H350fs)….The median TTR in patients with nonsense and frameshift CXCR4 mutations were 4 and 2 months, respectively (P = .31). Patients with CXCR4 mutations had a median TTMR of 10 months vs 3 months in patients without CXCR4 mutations.
Secondary therapy:
dexamethasone
DOI:
https://doi.org/10.1182/bloodadvances.2020001963
